{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:33:23Z","timestamp":1775165603254,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"],"award-info":[{"award-number":["RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FEDER via COMPETE, Portugal 2020 \u2013 Operational Programme for Competitiveness and Internationalization","award":["POCI-01-0145-FEDER-032188"],"award-info":[{"award-number":["POCI-01-0145-FEDER-032188"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Portugal & MedInUP","award":["UI\/BD\/150816\/2020"],"award-info":[{"award-number":["UI\/BD\/150816\/2020"]}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cysteinyl leukotrienes (CysLT) are potent inflammation-promoting mediators, but remain scarcely explored in COVID-19. We evaluated urinary CysLT (U-CysLT) relationship with disease severity and their usefulness for prognostication in hospitalized COVID-19 patients. The impact on U-CysLT of veno-venous extracorporeal membrane oxygenation (VV-ECMO) and of comorbidities such as hypertension and obesity was also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood and spot urine were collected in \u201csevere\u201d (<jats:italic>n<\/jats:italic>\u2009=\u200926), \u201ccritically ill\u201d (<jats:italic>n<\/jats:italic>\u2009=\u200917) and \u201ccritically ill on VV-ECMO\u201d (<jats:italic>n<\/jats:italic>\u2009=\u200917) patients with COVID-19 at days 1\u20132 (admission), 3\u20134, 5\u20138 and weekly thereafter, and in controls (<jats:italic>n<\/jats:italic>\u2009=\u200923) at a single time point. U-CysLT were measured by ELISA. Routine markers, prognostic scores and outcomes were also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>U-CysLT did not differ between groups at admission, but significantly increased along hospitalization only in critical groups, being markedly higher in VV-ECMO patients, especially in hypertensives. U-CysLT values during the first week were positively associated with ICU and total hospital length of stay in critical groups and showed acceptable area under curve (AUC) for prediction of 30-day mortality (AUC: 0.734, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) among all patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>U-CysLT increase during hospitalization in critical COVID-19 patients, especially in hypertensives on VV-ECMO. U-CysLT association with severe outcomes suggests their usefulness for prognostication and as therapeutic targets.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00011-022-01682-z","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T14:06:40Z","timestamp":1673186800000},"page":"475-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Marta","family":"Reina-Couto","sequence":"first","affiliation":[]},{"given":"Mariana","family":"Roboredo-Madeira","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pereira-Terra","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Silva-Pereira","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa","family":"Teixeira-Santos","sequence":"additional","affiliation":[]},{"given":"Dora","family":"Pinho","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo","family":"Cordeiro","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia Camila","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o T.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Roncon-Albuquerque","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Albino-Teixeira","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,1,8]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"publisher","first-page":"631139","DOI":"10.3389\/fimmu.2021.631139","volume":"12","author":"CR Triggle","year":"2021","unstructured":"Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021;12:631139.","journal-title":"Front Immunol."},{"key":"1682_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108427","volume":"215","author":"K Yuki","year":"2020","unstructured":"Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215: 108427.","journal-title":"Clin Immunol"},{"key":"1682_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138070","author":"S Li","year":"2020","unstructured":"Li S, Jiang L, Li X, Lin F, Wang Y, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.138070.","journal-title":"JCI Insight."},{"key":"1682_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383:120\u20138.","journal-title":"N Engl J Med"},{"key":"1682_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1\u201313.","journal-title":"Transl Res"},{"key":"1682_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1682_CR7","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3389\/fphar.2020.01214","volume":"11","author":"CD Funk","year":"2020","unstructured":"Funk CD, Ardakani A. A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes. Front Pharmacol. 2020;11:1214.","journal-title":"Front Pharmacol"},{"key":"1682_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11882-008-0057-z","volume":"8","author":"M Peters-Golden","year":"2008","unstructured":"Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr Allergy Asthma Rep. 2008;8:367\u201373.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1682_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bbagen.2011.02.005","volume":"1810","author":"K Okunishi","year":"2011","unstructured":"Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta. 2011;1810:1096\u2013102.","journal-title":"Biochim Biophys Acta"},{"key":"1682_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199009063231006","volume":"323","author":"RA Lewis","year":"1990","unstructured":"Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645\u201355.","journal-title":"N Engl J Med"},{"key":"1682_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-121-9-199411010-00010","volume":"121","author":"WR Henderson Jr","year":"1994","unstructured":"Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684\u201397.","journal-title":"Ann Intern Med"},{"key":"1682_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0140-6736(93)91073-U","volume":"341","author":"LA Laitinen","year":"1993","unstructured":"Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989\u201390.","journal-title":"Lancet"},{"key":"1682_CR13","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3390\/biomedicines10112845","volume":"10","author":"M Reina-Couto","year":"2022","unstructured":"Reina-Couto M, Santos-Oliveira M, Pereira-Terra P, Silva-Pereira C, Quelhas-Santos J, Duarte A, et al. Urinary cysteinyl leukotrienes as biomarkers of endothelial activation, inflammation and oxidative stress and their relationship with organ dysfunction in human septic shock. Biomedicines. 2022;10:2845.","journal-title":"Biomedicines."},{"key":"1682_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2222.2006.02498.x","volume":"36(6)","author":"M Peters-Golden","year":"2006","unstructured":"Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689-703.","journal-title":"Clin Exp. Allergy"},{"key":"1682_CR15","doi-asserted-by":"publisher","first-page":"608930","DOI":"10.1155\/2014\/608930","volume":"2014","author":"AJ Theron","year":"2014","unstructured":"Theron AJ, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:608930.","journal-title":"J Immunol Res."},{"key":"1682_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/0006-291X(81)91562-X","volume":"101","author":"S Hammarstr\u00f6m","year":"1981","unstructured":"Hammarstr\u00f6m S, Bernstr\u00f6m K, Orning L, Dahl\u00e9n SE, Hedqvist P. Rapid in vivo metabolism of leukotriene C3 in the monkey Macaca irus. Biochem Biophys Res Commun. 1981;101:1109\u201315.","journal-title":"Biochem Biophys Res Commun"},{"key":"1682_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0065-2571(89)90078-2","volume":"28","author":"D Keppler","year":"1989","unstructured":"Keppler D, Huber M, Baumert T, Guhlmann A. Metabolic inactivation of leukotrienes. Adv Enzyme Regul. 1989;28:307\u201319.","journal-title":"Adv Enzyme Regul"},{"key":"1682_CR18","first-page":"H244","volume":"263","author":"J Maclouf","year":"1992","unstructured":"Maclouf J, Antoine C, De Caterina R, Sicari R, Murphy RC, Patrignani P, et al. Entry rate and metabolism of leukotriene C4 into vascular compartment in healthy subjects. Am J Physiol. 1992;263:H244\u20139.","journal-title":"Am J Physiol"},{"key":"1682_CR19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJMra071371","volume":"357","author":"M Peters-Golden","year":"2007","unstructured":"Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357:1841\u201354.","journal-title":"N Engl J Med"},{"key":"1682_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.4049\/jimmunol.173.3.1503","volume":"173","author":"Y Kanaoka","year":"2004","unstructured":"Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004;173:1503\u201310.","journal-title":"J Immunol"},{"key":"1682_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1365-2222.2008.02963.x","volume":"38","author":"F Tahan","year":"2008","unstructured":"Tahan F, Jazrawi E, Moodley T, Rovati GE, Adcock IM. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin Exp Allergy. 2008;38:805\u201311.","journal-title":"Clin Exp Allergy"},{"key":"1682_CR22","doi-asserted-by":"publisher","first-page":"610132","DOI":"10.3389\/fmolb.2020.610132","volume":"7","author":"L Aigner","year":"2020","unstructured":"Aigner L, Pietrantonio F, Bessa de Sousa DM, Michael J, Schuster D, Reitsamer HA, et al. The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic. Front Mol Biosci. 2020;7:610132.","journal-title":"Front Mol Biosci"},{"key":"1682_CR23","doi-asserted-by":"publisher","first-page":"2001227","DOI":"10.1183\/13993003.01227-2020","volume":"55","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2001227.","journal-title":"Eur Respir J"},{"key":"1682_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"1682_CR25","doi-asserted-by":"publisher","first-page":"2001148","DOI":"10.1183\/13993003.01148-2020","volume":"55","author":"CE Leiva Sisnieguez","year":"2020","unstructured":"Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020;55:2001148.","journal-title":"Eur Respir J"},{"key":"1682_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3377","volume":"37","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021;37: e3377.","journal-title":"Diabetes Metab Res Rev"},{"key":"1682_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13128","volume":"21","author":"BM Popkin","year":"2020","unstructured":"Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21: e13128.","journal-title":"Obes Rev"},{"key":"1682_CR28","volume":"370","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370: m3379.","journal-title":"BMJ"},{"issue":"119","key":"1682_CR29","first-page":"272","volume":"2015","author":"JR Bood","year":"1985","unstructured":"Bood JR, Sundblad BM, Delin I, Sjodin M, Larsson K, Anderson SD, et al. Urinary excretion of lipid mediators in response to repeated eucapnic voluntary hyperpnea in asthmatic subjects. J Appl Physiol. 1985;2015(119):272\u20139.","journal-title":"J Appl Physiol"},{"key":"1682_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1682_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2362.2009.02234.x","volume":"40","author":"I Simera","year":"2010","unstructured":"Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35\u201353.","journal-title":"Eur J Clin Invest"},{"key":"1682_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1056\/NEJMoa1800385","volume":"378","author":"A Combes","year":"2018","unstructured":"Combes A, Hajage D, Capellier G, Demoule A, Lavou\u00e9 S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378:1965\u201375.","journal-title":"N Engl J Med"},{"key":"1682_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(09)61069-2","volume":"374","author":"GJ Peek","year":"2009","unstructured":"Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351\u201363.","journal-title":"Lancet"},{"key":"1682_CR34","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14715","volume":"9","author":"R Giraud","year":"2021","unstructured":"Giraud R, Legouis D, Assouline B, De Charriere A, Decosterd D, Brunner ME, et al. Timing of VV-ECMO therapy implementation influences prognosis of COVID-19 patients. Physiol Rep. 2021;9: e14715.","journal-title":"Physiol Rep"},{"key":"1682_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/MAT.0000000000001422","volume":"67","author":"J Badulak","year":"2021","unstructured":"Badulak J, Antonini MV, Stead CM, Shekerdemian L, Raman L, Paden ML, et al. Extracorporeal Membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization. Asaio j. 2021;67:485\u201395.","journal-title":"Asaio j"},{"key":"1682_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.exger.2005.04.004","volume":"40","author":"S Gangemi","year":"2005","unstructured":"Gangemi S, Pescara L, D\u2019Urbano E, Basile G, Nicita-Mauro V, Dav\u00ec G, et al. Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol. 2005;40:612\u20134.","journal-title":"Exp Gerontol"},{"key":"1682_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MAT.0000000000001193","volume":"66","author":"K Shekar","year":"2020","unstructured":"Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. Asaio\u00a0J. 2020;66:707\u201321.","journal-title":"Asaio\u00a0J"},{"key":"1682_CR38","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1053\/j.jvca.2021.11.006","volume":"36","author":"P Bertini","year":"2022","unstructured":"Bertini P, Guarracino F, Falcone M, Nardelli P, Landoni G, Nocci M, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022;36:2700\u20136.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1682_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature"},{"key":"1682_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1164\/rccm.201012-2039OC","volume":"184","author":"RC Li","year":"2011","unstructured":"Li RC, Haribabu B, Mathis SP, Kim J, Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med. 2011;184:124\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"1682_CR41","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.4049\/jimmunol.0902594","volume":"184","author":"CS Gonsalves","year":"2010","unstructured":"Gonsalves CS, Kalra VK. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a\u20135p. J Immunol. 2010;184:3878\u201388.","journal-title":"J Immunol"},{"key":"1682_CR42","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1194\/jlr.P022814","volume":"53","author":"F Stanke-Labesque","year":"2012","unstructured":"Stanke-Labesque F, P\u00e9pin JL, de Jouvencel T, Arnaud C, Baguet JP, Petri MH, et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res. 2012;53:1944\u201351.","journal-title":"J Lipid Res"},{"key":"1682_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cvr\/cvt247","volume":"101","author":"F Stanke-Labesque","year":"2014","unstructured":"Stanke-Labesque F, P\u00e9pin JL, Gautier-Veyret E, L\u00e9vy P, B\u00e4ck M. Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res. 2014;101:187\u201393.","journal-title":"Cardiovasc Res"},{"issue":"364\u201370","key":"1682_CR44","first-page":"370.e1","volume":"124","author":"F Stanke-Labesque","year":"2009","unstructured":"Stanke-Labesque F, B\u00e4ck M, Lefebvre B, Tamisier R, Baguet JP, Arnol N, et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol. 2009;124(364\u201370):370.e1-2.","journal-title":"J Allergy Clin Immunol"},{"key":"1682_CR45","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.RES.0000264498.60702.0d","volume":"100","author":"M B\u00e4ck","year":"2007","unstructured":"B\u00e4ck M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res. 2007;100:946\u20139.","journal-title":"Circ Res"},{"key":"1682_CR46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2337\/db11-1455","volume":"61","author":"I Mothe-Satney","year":"2012","unstructured":"Mothe-Satney I, Filloux C, Amghar H, Pons C, Bourlier V, Galitzky J, et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012;61:2311\u20139.","journal-title":"Diabetes"},{"key":"1682_CR47","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1097\/FJC.0000000000001116","volume":"78","author":"M Peng","year":"2021","unstructured":"Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of hypertension on the severity of COVID-19: a review. J Cardiovasc Pharmacol. 2021;78:e648\u201355.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1682_CR48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/jmv.26050","volume":"92","author":"W Tian","year":"2020","unstructured":"Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2020;92:1875\u201383.","journal-title":"J Med Virol"},{"key":"1682_CR49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrd1796","volume":"4","author":"CD Funk","year":"2005","unstructured":"Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664\u201372.","journal-title":"Nat Rev Drug Discov"},{"key":"1682_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/cvr\/cvq016","volume":"86","author":"D Poeckel","year":"2010","unstructured":"Poeckel D, Funk CD. The 5-lipoxygenase\/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res. 2010;86:243\u201353.","journal-title":"Cardiovasc Res"},{"key":"1682_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0008-6363(00)00238-8","volume":"49","author":"F Stanke-Labesque","year":"2001","unstructured":"Stanke-Labesque F, Devillier P, Veitl S, Caron F, Cracowski JL, Bessard G. Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. Cardiovasc Res. 2001;49:152\u201360.","journal-title":"Cardiovasc Res"},{"key":"1682_CR52","doi-asserted-by":"publisher","first-page":"H342","DOI":"10.1152\/ajpheart.2001.281.1.H342","volume":"281","author":"S Shastri","year":"2001","unstructured":"Shastri S, McNeill JR, Wilson TW, Poduri R, Kaul C, Gopalakrishnan V. Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. Am J Physiol Heart Circ Physiol. 2001;281:H342\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1682_CR53","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0008-6363(00)00112-7","volume":"47","author":"F Stanke-Labesque","year":"2000","unstructured":"Stanke-Labesque F, Devillier P, Bedouch P, Cracowski JL, Chavanon O, Bessard G. Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition. Cardiovasc Res. 2000;47:376\u201383.","journal-title":"Cardiovasc Res"},{"key":"1682_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00004872-200202000-00016","volume":"20","author":"F Stanke-Labesque","year":"2002","unstructured":"Stanke-Labesque F, Hardy G, Vergnaud S, Devillier P, Peoc\u2019h M, Randon J, et al. Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats. J Hypertens. 2002;20:263\u201372.","journal-title":"J Hypertens"},{"key":"1682_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4049\/jimmunol.2001025","volume":"206","author":"B Schwarz","year":"2021","unstructured":"Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, et al. Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators. J Immunol. 2021;206:329\u201334.","journal-title":"J Immunol"},{"key":"1682_CR56","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100540R","volume":"35","author":"AS Archambault","year":"2021","unstructured":"Archambault AS, Zaid Y, Rakotoarivelo V, Turcotte C, Dor\u00e9 \u00c9, Dubuc I, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. Faseb j. 2021;35: e21666.","journal-title":"Faseb j"},{"key":"1682_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0952-3278(03)00074-7","volume":"69","author":"C Bandeira-Melo","year":"2003","unstructured":"Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids. 2003;69:135\u201343.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1682_CR58","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fmed.2017.00106","volume":"4","author":"GA Thompson-Souza","year":"2017","unstructured":"Thompson-Souza GA, Gropillo I, Neves JS. Cysteinyl leukotrienes in eosinophil biology: functional roles and therapeutic perspectives in eosinophilic disorders. Front Med (Lausanne). 2017;4:106.","journal-title":"Front Med (Lausanne)"},{"key":"1682_CR59","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.201301-0023PP","volume":"188","author":"JP Scott","year":"2013","unstructured":"Scott JP, Peters-Golden M. Antileukotriene agents for the treatment of lung disease. Am J Respir Crit Care Med. 2013;188:538\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"1682_CR60","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan. China Clin Infect Dis. 2020;71:762\u20138.","journal-title":"China Clin Infect Dis"},{"key":"1682_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109798","volume":"37","author":"DM Kim","year":"2021","unstructured":"Kim DM, Kim Y, Seo JW, Lee J, Park U, Ha NY, et al. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell Rep. 2021;37: 109798.","journal-title":"Cell Rep"},{"key":"1682_CR62","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/2050640620924157","volume":"8","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020;8:509\u201319.","journal-title":"United European Gastroenterol J"},{"key":"1682_CR63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/10408363.2020.1770685","volume":"57","author":"G Ponti","year":"2020","unstructured":"Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57:389\u201399.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1682_CR64","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/apt.15916","volume":"52","author":"AV Kulkarni","year":"2020","unstructured":"Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52:584\u201399.","journal-title":"Aliment Pharmacol Ther"},{"key":"1682_CR65","doi-asserted-by":"publisher","first-page":"6974","DOI":"10.1073\/pnas.87.18.6974","volume":"87","author":"RJ Sebaldt","year":"1990","unstructured":"Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ 2nd, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA. 1990;87:6974\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1682_CR66","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1183\/09031936.93.05060712","volume":"5","author":"G Manso","year":"1992","unstructured":"Manso G, Baker AJ, Taylor IK, Fuller RW. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J. 1992;5:712\u20136.","journal-title":"Eur Respir J"},{"key":"1682_CR67","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0954-6111(03)00253-1","volume":"97","author":"I Vachier","year":"2003","unstructured":"Vachier I, Kumlin M, Dahl\u00e9n SE, Bousquet J, Godard P, Chanez P. High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med. 2003;97:1225\u20139.","journal-title":"Respir Med"},{"key":"1682_CR68","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jaci.2008.02.007","volume":"121","author":"J Negri","year":"2008","unstructured":"Negri J, Early SB, Steinke JW, Borish L. Corticosteroids as inhibitors of cysteinyl leukotriene metabolic and signaling pathways. J Allergy Clin Immunol. 2008;121:1232\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1682_CR69","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.imlet.2007.02.001","volume":"109","author":"E Brzezinska-Blaszczyk","year":"2007","unstructured":"Brzezinska-Blaszczyk E, Rdzany RS. Lipoteichoic acids selectively stimulate rat mast cells to cysteinyl leukotriene generation and affect mast cell migration after tumor necrosis factor (TNF)-priming. Immunol Lett. 2007;109:138\u201344.","journal-title":"Immunol Lett"},{"key":"1682_CR70","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/ALN.0b013e31822e94bd","volume":"115","author":"B Petersen","year":"2011","unstructured":"Petersen B, Austen KF, Bloch KD, Hotta Y, Ichinose F, Kanaoka Y, et al. Cysteinyl leukotrienes impair hypoxic pulmonary vasoconstriction in endotoxemic mice. Anesthesiology. 2011;115:804\u201311.","journal-title":"Anesthesiology"},{"key":"1682_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock J, Chalmers JD. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther. 2021;71: 102095.","journal-title":"Pulm Pharmacol Ther"},{"key":"1682_CR72","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000518359","volume":"106","author":"M Dey","year":"2021","unstructured":"Dey M, Singh RK. Possible therapeutic potential of cysteinyl leukotriene receptor antagonist montelukast in treatment of SARS-CoV-2-induced COVID-19. Pharmacology. 2021;106:469\u201376.","journal-title":"Pharmacology"},{"key":"1682_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00482-8","author":"S Bohnacker","year":"2022","unstructured":"Bohnacker S, Hartung F, Henkel F, Quaranta A, Kolmert J, Priller A, et al. Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages. Mucosal Immunol. 2022. https:\/\/doi.org\/10.1038\/s41385-021-00482-8.","journal-title":"Mucosal Immunol"},{"key":"1682_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256226","volume":"16","author":"F Palmas","year":"2021","unstructured":"Palmas F, Clarke J, Colas RA, Gomez EA, Keogh A, Boylan M, et al. Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS\u00a0One. 2021;16: e0256226.","journal-title":"PLoS\u00a0One"},{"key":"1682_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.784214","volume":"13","author":"M Camera","year":"2022","unstructured":"Camera M, Canzano P, Brambilla M, Rovati GE. Montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Front Pharmacol. 2022;13: 784214.","journal-title":"Front Pharmacol"},{"key":"1682_CR76","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1080\/02770903.2020.1786112","volume":"58","author":"A Bozek","year":"2021","unstructured":"Bozek A, Winterstein J. Montelukast\u2019s ability to fight COVID-19 infection. J Asthma. 2021;58:1348\u20139.","journal-title":"J Asthma"},{"key":"1682_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2021.1881967:1-7","author":"AR Khan","year":"2021","unstructured":"Khan AR, Misdary C, Yegya-Raman N, Kim S, Narayanan N, Siddiqui S, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2021. https:\/\/doi.org\/10.1080\/02770903.2021.1881967:1-7.","journal-title":"J Asthma"},{"key":"1682_CR78","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2022.401","volume":"6","author":"PL Elkin","year":"2022","unstructured":"Elkin PL, Resendez S, Mullin S, Troen BR, Mammen MJ, Chang S, et al. Leukotriene inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations. J Clin Transl Sci. 2022;6: e74.","journal-title":"J Clin Transl Sci"},{"key":"1682_CR79","unstructured":"Wilchesky M, Tranmer G, Grad R. The COvid-19 Symptom MOntelukast trial (COSMO). 2020; Identifier NCT04389411. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04389411."},{"key":"1682_CR80","unstructured":"Almeda Ortega J, Bonet Monne S, Salvador Gonzalez B, Mera Cordero F. Efficacy of montelukast in mild-moderate respiratory symptoms in patients with long-COVID-19: (E-SPERANZA). 2021. Identifier NCT04695704. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04695704."},{"key":"1682_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/j.pbj.0000000000000134","volume":"6","author":"M Tavares","year":"2021","unstructured":"Tavares M, Farraia M, Silva S, Ribeiro AM, Severo M, Paci\u00eancia I, et al. Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial. Porto Biomed J. 2021;6: e134.","journal-title":"Porto Biomed J"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-022-01682-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01682-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T19:05:49Z","timestamp":1679079949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-022-01682-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,8]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1007\/s00011-022-01682-z","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,8]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The CHUSJ Health Ethics Committee approved this study [CES 75-16], with project amended specifically for inclusion of subjects with COVID-19, within the scope of a RESEARCH 4 COVID-19 grant from FCT (special support for rapid implementation projects for innovative response solutions to COVID-19 pandemic)].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All eligible patients provided written informed consent to participate in the study. For ICU patients unable to give consent, this was solicited to their next of kin. These patients provided informed consent retrospectively, where possible. Blood donor volunteers provided oral informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors agree to publish this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}